Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.8% - Time to Sell?

Shares of Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) traded down 2.8% on Wednesday . The company traded as low as $8.48 and last traded at $8.69. 35,969 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 40,781 shares. The stock had previously closed at $8.94.

Actuate Therapeutics Stock Down 1.4 %

The stock has a fifty day simple moving average of $7.69. The company has a market cap of $164.85 million and a price-to-earnings ratio of 57.93.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its quarterly earnings data on Tuesday, September 24th. The company reported ($4.20) EPS for the quarter.

Insider Activity at Actuate Therapeutics

In related news, major shareholder Leslie W. Kreis sold 24,999 shares of Actuate Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total transaction of $224,991.00. Following the transaction, the insider now owns 131,248 shares of the company's stock, valued at $1,181,232. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, major shareholder Leslie W. Kreis sold 24,999 shares of the firm's stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $9.00, for a total transaction of $224,991.00. Following the transaction, the insider now directly owns 131,248 shares of the company's stock, valued at $1,181,232. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Equity Cof Lp Bios acquired 500,000 shares of Actuate Therapeutics stock in a transaction on Wednesday, August 14th. The stock was purchased at an average cost of $8.00 per share, with a total value of $4,000,000.00. Following the completion of the transaction, the director now directly owns 1,259,427 shares in the company, valued at $10,075,416. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 19.90% of the stock is owned by insiders.

Institutional Trading of Actuate Therapeutics

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC purchased a new position in shares of Actuate Therapeutics (NASDAQ:ACTU - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 12,000 shares of the company's stock, valued at approximately $89,000. KG&L Capital Management LLC owned about 0.06% of Actuate Therapeutics as of its most recent SEC filing. 78.29% of the stock is owned by institutional investors and hedge funds.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.